The massive farm bill changes some sacred cow items like crop insurance and commodity subsidies but gives aid for crops out of the mainstream.» Read More
The man who oversees the insurance operations for Warren Buffett's Berkshire Hathaway tells CNBC that Berkshire is talking with troubled bond insurers like MBIA and Ambac about a possible partnership or purchase, although it doesn't sound like anything major is imminent. Ajit Jain's comment came in response to a question from Erin Burnett in a live interview on CNBC's Street Signs about why Berkshire chose to "build" its own bond insurer rather than buy an existing company like Ambac or MBIA.
Former American International Group Chief Executive Maurice "Hank" Greenberg said that a group he represents currently does not intend to solicit proxies from AIG shareholders, buy more AIG shares, or initiate a tender offer for the company.
The soda giant is going to $70, Cramer says. Also, the stocks that will signal the end of the Nasdaq decline.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
A criminal corporate fraud trial that could bring Warren Buffett to the witness stand for some tough questioning is now underway in a federal courthouse in Hartford, Connecticut. Emphasis on could. Here's why I have my doubts.
Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.
In a research note to clients this morning, Miller Tabak healthcare analyst Les Funtleyder writes about the FDA news I blogged about yesterday regarding Amgen's anemia drugs. He says, "...we believe the major 'leg down' in usage (of the anemia drugs) was last year and more studies assuming no major new negative revelations will only serve to continue deterioration but at a decelerating rate."
The legendary investor just finished his second bad year in a row. So LM's a sell. But there's more to it than that, Cramer explains.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
A federal judge overseeing the trial of four former executives at the General Re unit of Berkshire Hathaway said the reinsurer need not turn over some documents involving Berkshire Chairman Warren Buffett.
The "Dendreonians" have probably already seen it, but I wanted to call your attention to a pretty long piece that ran in the health section of the Los Angeles Times on Dec. 31st. It's about the grass-roots movement to get Dendreon's prostate cancer drug, Provenge, approved by the FDA. Here's the link.
Warren Buffett is finally moving to make some money from the nation's credit crisis by starting a new company that will insure debt issued by state and local governments. To make sure that he does indeed make money from the venture, he's promising not to make the same mistakes that have caused so many problems for long-time insurers like Ambac and MBIA: charging too little and taking on too much risk.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
ACA Capital Holdings said Maryland state regulators will now make many significant business decisions for its main bond insurance unit, as the bond insurer tries to stave off a cash crunch.
A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.
This year was marked by an absence of "megacatastrophes" but an increase in the number of smaller-scale natural disasters caused higher losses than the insurance industry saw in 2006, Munich Re said.
Shares of drugmaker Wyeth could remain under pressure this day after Christmas. At least two analysts are suggesting that Wyeth could be under assault by another generic drug company.
MBIA CEO Gary Dunton "has the touch of a great novelist" when it comes to the company's financial reports, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.
Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.
Top European lender HSBC Holdings, which is building up its global insurance business, may strike a distribution partnership in fast-growing China in 2008, its Asia chief said on Wednesday.
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.